VRDN
Research Snapshot
Static fundamentals, valuation context, and investor signals for Viridian Therapeutics, Inc.\DE (VRDN).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-47.4%
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 12.6x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for VRDN.
Grade F
1
/ 100
Quality Radar0 – 20 per axis